Related Experiment Video
Updated: Jul 12, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
[Sodium-glucose cotransporter 2 inhibitors for the management of heart failure]
Ana Nouel1, José Luis Winter1, Luis Sepúlveda1
1Departamento de Enfermedades Cardiovasculares, Clínica Alemana de Santiago, Santiago, Chile.
Insights
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) show significant benefits for patients with heart failure (HF), reducing cardiovascular events. This review examines their effectiveness in adults with HF, regardless of ejection fraction, especially those with type 2 diabetes mellitus (DM2).
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Abstract:
Heart failure (HF) is a global health problem. There is a strong association h between HF and type 2 diabetes mellitus (DM2), with an increasing prevalence of patients having both conditions concomitantly. Sodium-glucose cotransporter 2 inhibitors (ISGLT2) significantly reduce cardiovascular events, including cardiovascular death. In this article we will focus on the current evidence about the effectiveness of these medications in adults with heart failure with reduced or preserved ejection fraction.
More Related Videos
08:47Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
Related Concept Videos
Heart Failure V: Medical Management
Secondary Active Transport
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System